Anectine Generic Name & Formulations
Anectine Dosage and Administration
Genetic susceptibility to malignant hyperthermia. Skeletal muscle myopathies. Acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury.
Anectine Boxed Warnings
To be administered only by those skilled in management of artificial respiration. Have intubation, adequate ventilation, oxygen therapy available. Should not be administered prior to induction of unconsciousness (unless emergency). Pretreatment with anticholinergic agents (eg, atropine) may reduce occurence of bradyarrythmias. Caution in patients with reduced plasma cholinesterase activity in presence of gene abnormalities (eg, heterozygous or homozygous for atypical plasma cholinesterase gene), pregnancy, severe hepatic or renal disease, malignant tumors, infections, burns, anemia, heart disease, peptic ulcer, myxedema, or drugs affecting cholinesterase activity (see Interactions). Electrolyte abnormalities, digitalis toxicity, acute phase of injury (see Contraindications), chronic abdominal infection, subarachnoid hemorrhage, or conditions causing degeneration of central and peripheral nervous systems: increased risk of hyperkalemia. Risk of malignant hyperthermia; discontinue all triggering agents if suspected (eg, volatile anesthetic agents, succinylcholine). Risk of medication errors; confirm proper selection of intended product and ensure dose is clearly labeled/communicated. Monitor for possible transition into Phase II block (see full labeling). Glaucoma or eye injury. Bone fractures or muscle spasm. Neuromuscular blockade may be prolonged in hypokalemia or hypocalcemia. Children with skeletal muscle myopathy. Elderly. Pregnancy. Labor & delivery. Nursing mothers.
Anectine Adverse Reactions
Anectine Clinical Trials
Anectine Patient Counseling